Cancers with wrong HATs: the impact of acetylation

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Lysine N-ε-acetylation is a key post-translational modification regulating histone and non-histone protein functions.
• Dysregulated histone acetyltransferase (HAT) activity, due to genetic or epigenetic changes, is implicated in various malignancies.
• Altered acetylation profiles can indicate pathological processes and serve as predictive biomarkers for patient survival and therapy response.

Purpose of the Study:

• To explore the role of lysine acetylation in cancer.
• To highlight the potential of histone acetylation evaluation as a predictive index.
• To emphasize the promise of epigenetic therapy in cancer treatment.

Main Methods:

• Review of literature on lysine acetylation, HATs, and epigenetic alterations in cancer.
• Analysis of the dual role of HATs as tumor suppressors and oncogenes.
• Discussion of therapeutic strategies targeting acetylation pathways.

Main Results:

• Histone acetylation status is altered in malignancies, impacting cellular proliferation and cell cycle control.
• Abnormal acetylation can activate oncogenic proteins, contributing to cancer progression.
• Histone acetylation evaluation shows potential as a predictive biomarker for patient outcomes.

Conclusions:

• Epigenetic modifications, particularly lysine acetylation, are critical in cancer pathogenesis.
• Targeting acetylation pathways with epigenetic drugs, such as HAT inhibitors and bromodomain inhibitors, offers a promising therapeutic strategy.
• Epigenetic therapy holds significant potential for controlling human diseases, including cancer.